The Application of Proteomics to PK-PD Modeling and Simulation
Ken-ichi Sako1, Hisao Haniu2, Mayumi Hasegawa3, Hirohisa Doi3, Shunsuke Yano3, Yuichiro Oosawa3, Tohru Kishino3, Yoshihiko Matsuki4, Yumiko Arisue1, Takeshi Kawamura1, Masayuki Kimura1and Yoshikazu Matsuda1*
- *Corresponding Author:
- Dr. Yoshikazu Matsuda
Clinical Pharmaceutics Educational Center
Nihon Pharmaceutical University
10281 Komuro, Ina-machi, Saitama 362-0806, Japan
E-mail: [email protected]
Received Date: August 12, 2011; Accepted Date: September 17, 2011; Published Date: September 19, 2011
Citation: Sako KI, Haniu H, Hasegawa M, Doi H, Yano S, et al. (2011) The Application of Proteomics to PK-PD Modeling and Simulation. J Bioequiv Availab S2. doi: 10.4172/jbb.S2-002
Copyright: © 2011 Sako KI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation can be an invaluable tool for use in making crucial decisions in drug development and clinical settings, including those pertaining to compound selection, dose selection, study design, and patient population, all of which can impact the cost of development and treatment. Clinical PK-PD modeling and simulation of antimicrobial agents are possible because minimum inhibitory concentration (MIC) values can be easily measured in the hospital laboratory. However, no such easily measured clinical markers are available for many other types of drugs. In this point of view, we thought that the proteomics approach may be available for find the direct PD parameter such as drug specific biomarker. Many reports also suggest that proteomics is a promising tool in the search for drug-specific biomarker proteins that could be used in PK-PD modeling and simulation. Thus, by enabling examination of drug-induced changes in the expression of specific biomarker proteins, proteomic data could be used in PD analyses in much the same way that MICs are used in PD evaluations of antimicrobial agents.